Technical Analysis for VCNX - Vaccinex, Inc.

Grade Last Price % Change Price Change
F 2.95 5.73% 0.16
VCNX closed up 5.73 percent on Friday, November 1, 2024, on 55 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: Nov 11
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Fell Below 50 DMA Bearish 5.73%
Stochastic Sell Signal Bearish 5.73%
Expansion Pivot Sell Setup Bearish Swing Setup 5.73%
Volume Surge Other 5.73%
Wide Range Bar Range Expansion 5.73%
Outside Day Range Expansion 5.73%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 20 hours ago
1.5x Volume Pace 1 day ago
Up 5% 1 day ago
Up 3% 1 day ago
Expansion Pivot Sell Entry 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vaccinex, Inc. Description

Vaccinex Inc. is a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics. The Company is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. It also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Biology Immunology Immune System Clinical Development Antibodies Monoclonal Antibodies Antibody Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Multiple Sclerosis Neurodegenerative Diseases Sarcoma Autoimmune Disorders Degenerative Disease Immune Disorders NSCLC Treatment Of Non Small Cell Lung Cancer Human Monoclonal Antibodies Osteosarcoma Treatment Of Multiple Sclerosis Seth Lederman Vaccinia

Is VCNX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 13.44
52 Week Low 1.39
Average Volume 93,188
200-Day Moving Average 6.14
50-Day Moving Average 3.93
20-Day Moving Average 2.72
10-Day Moving Average 3.23
Average True Range 0.60
RSI (14) 45.65
ADX 22.51
+DI 23.86
-DI 19.72
Chandelier Exit (Long, 3 ATRs) 3.00
Chandelier Exit (Short, 3 ATRs) 3.20
Upper Bollinger Bands 4.01
Lower Bollinger Band 1.44
Percent B (%b) 0.59
BandWidth 94.39
MACD Line -0.09
MACD Signal Line -0.23
MACD Histogram 0.1465
Fundamentals Value
Market Cap 36.86 Million
Num Shares 12.5 Million
EPS -5.99
Price-to-Earnings (P/E) Ratio -0.49
Price-to-Sales 10.83
Price-to-Book 3.05
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.28
Resistance 3 (R3) 3.25 3.10 3.22
Resistance 2 (R2) 3.10 3.02 3.12 3.21
Resistance 1 (R1) 3.03 2.97 3.06 3.06 3.19
Pivot Point 2.88 2.88 2.90 2.90 2.88
Support 1 (S1) 2.81 2.80 2.85 2.84 2.71
Support 2 (S2) 2.66 2.75 2.68 2.69
Support 3 (S3) 2.59 2.66 2.68
Support 4 (S4) 2.62